促性腺激素释放激素2（GNRH2）是一种研究不多的多肽激素，广泛分布于哺乳动物的中枢神经系统及周围组织中。非同义突变rs6051545在GNRH2（A16V）中与血清睾丸酮浓度升高有关。本研究调查了A16V突变是否与雄激素剥夺疗法（ADT）进展无病生存期（PFS）和总生存期（OS）的改变相关。我们使用免疫荧光法检测了GNRH2在前列腺组织微阵列中的表达情况，包括正常组织、前列腺增生和前列腺癌。我们还评估了131例接受ADT的前列腺癌患者的GNRH2基因型，并比较了突变型基因型和野生型基因型之间的PFS和OS。虽然GNRH2在所有前列腺组织中都有检测到，但其表达与格里森评分或疾病分期无关（p=0.71）。GNRH2 A16V基因型与PFS或OS无关，但单变量和多变量分析显示格里森评分和局部治疗明确与PFS相关（p≤0.0074），而年龄和格里森评分与OS相关（p≤0.0046）。GNRH2在正常、增生和恶性前列腺组织中均有表达，A16V突变与治疗结果或生存无关。© 2023年国际抗癌研究所（George J. Delinasios博士）保留所有权利。

Gonadotropin-releasing hormone 2 (GNRH2) is a poorly-studied peptide hormone that is widely distributed in the central nervous system and expressed in peripheral tissues of mammals. The non-synonymous rs6051545 variant in GNRH2 (A16V) has been linked to higher serum testosterone concentrations. This study investigated whether the A16V variant is associated with altered androgen-deprivation therapy (ADT) progression-free survival (PFS) and overall survival (OS).We examined the expression of GNRH2 in prostate tissue microarrays comprising normal tissue, prostatic hyperplasia, and prostate cancer using immunofluorescence. We also evaluated the GNRH2 genotype in 131 patients with prostate cancer who received ADT and compared PFS and OS between the variant and wild-type genotypes.GNRH2 was detected in all prostate tissues, although expression did not vary with Gleason grade or disease stage (p=0.71). The GNRH2 A16V genotype was not associated with PFS or OS; however, univariate and multivariate analyses revealed Gleason score and definitive local therapy were each associated with PFS (p≤0.0074), whereas age and Gleason score were associated with OS (p≤0.0046).GNRH2 is expressed in normal, hyperplastic, and neoplastic prostate tissues; the A16V variant is not related to treatment outcome or survival.Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.